Mutations in the fibroblast growth factor receptor (FGFR) gene family recently have been shown to underlie several hereditary disorders of bone development, with specific FGFR3 mutations causing achondroplasia (Ach) and thanatophoric dysplasia (TD). However, for none of these mutations has the defect in receptor function been demonstrated directly and, therefore, for none has the pathophysiological mechanism of the disease been defined. Using our established techniques for single-cell ratiometric realtime calcium image analysis, we defined the nature of the basic fibroblast growth factor (bFGF)-induced calcium signal in human diploid fibroblasts, and, in blinded studies, have analyzed the bFGF-induced signals from 18 independent fibroblast cell lines, including multiple lines from patients with known mutant alleles of FGFR3 and syndromes of Ach or TD. Control cells responded with transient increases in intracellular calcium, with many cells showing oscillatory calcium waves. Homozygous Ach cell lines failed to signal, whereas heterozygous Ach lines responded nearly normally. We observed heterogeneous signals in TD heterozygotes: the unresponsive lines all turned out to carry TD1 alleles, whereas all responsive lines had TD2 alleles. Since FGFR1, 2 and 3 receptors are known to be expressed in fibroblasts, our results suggest that specific mutant FGFR3 alleles can function in a dosage-dependent dominant-negative fashion to inactivate FGFR signaling.
INTRODUCTION
Mutations in the fibroblast growth factor receptor (FGFR) gene family recently have been shown to underlie several dominantly inherited disorders of bone development. FGFR1 mutations have been shown to produce Pfeiffer syndrome, FGFR2 mutations have been shown to produce Crouzon, Jackson-Weiss, Pfeiffer and Apert syndrome, and FGFR3 mutations have been shown to cause achondroplasia (Ach), thanatophoric dysplasia (TD) types 1 and 2, hypochondroplasia, Crouzon syndrome with acanthosis nigricans and FGFR3-associated coronal synostosis syndrome (1,2; reviewed in 3,4). All of the mutant disease-causing alleles found in the three receptor types are dominant, mutations at different FGFR loci can give the same disease phenotype, a given allele can produce different disease phenotypes and the majority of the different alleles even appear to alter a common structure, the receptor dimer. This suggests that mutations in all three types of FGFR share a common pathophysiological mechanism. However, for none of these mutations has the defect in receptor function been demonstrated directly.
A number of groups have taken simplifying indirect approaches to approximate the pathophysiology of the FGFR mutations. These studies have entailed either the use of conventional knockout mice (5, 6) or in vitro studies of transfected chimeric receptors (7) (8) (9) (10) . Such studies allow one to sample different aspects of physiological FGFR signaling, but neither fully recapitulates the native or disease state. It has long been recognized that most tissues express multiple FGFR types, including splice variants of each, that most FGF ligands discriminate poorly between the receptor types and that both hetero-and homoreceptor dimers contribute to signaling (11) . Engineered dominant-negative alleles have provided the best demonstration of this interaction, and have proven useful tools in the analysis of FGFR function (12) (13) (14) . Model dominant-negative mutations in one receptor class can create a dosage-dependent inhibition of all FGF signaling, even though many wild-type FGF receptors of the same and different type are expressed. This kind of interaction between the FGFR types has been defined in transfected cultured cells (12) , injected Xenopus oocytes (12) and embryos (13) , and the epidermis of transgenic mice (14) . Since, to date, attempts to define the pathogenesis of the FGFR diseases have been limited to an analysis of either null alleles in vivo or expression of only the targeted mutant receptor itself in isolation in vitro, there has not yet been the potential to observe physiological signaling interactions between the host of receptors, expressed by most tissues, that are capable of responding in concert to the presence of FGF ligand. Since neither the knockout mice nor the transfectant systems have the potential to observe this type of physiological interaction, neither has had the potential *To whom correspondence should be addressed. Tel: +1 714 824 7702; Fax: +1 714 824 8540; Email: jjgargus@uci.edu to examine this well understood dominant-negative pathophysiological mechanism (15) .
FGFR signaling has been studied most extensively in the model systems of the Xenopus oocyte and several cultured cell lines (12, 16 and reviewed in 11). In both systems, FGF-induced intracellular calcium waves have been a reproducible part of the physiological signal, and such calcium signals increasingly have been recognized to be central and integrating components of the signals produced by the two major classes of transmembrane receptors that couple through the RAF and MAP kinases, the growth factor receptor tyrosine kinases and the G protein-coupled serpentine receptors (17, 18) . While the molecular nature of the membrane proteins involved in calcium signaling, and the exact functional consequences of these signals, remain open active areas of research, the fundamental membrane events underlying the generation of calcium waves themselves are already well defined (19) .
For all of the above reasons, we felt that it would be valuable to assess directly FGF-induced calcium signals in the physiological preparation of cultured diploid fibroblasts natively expressing defined mutant FGFR3 alleles. We carried out an examination of FGF2/basic fibroblast growth factor (bFGF)-induced intracellular calcium signals in 18 independent human fibroblast cell lines, blinded to their genotype. These cells, originally obtained from affected patients, were known to be expressing specific mutant alleles, since RT-PCR of mRNA from these very cells led to the original definition of the disease gene in the laboratory of Dr J. J. Wasmuth (20, 21) . In addition, they should present a better model of the disease process than those models used to date since they not only physiologically express FGFR3 from genomic DNA (20, 21) , meaning all splice variants can be naturally produced, but they, like most tissues (11), also express FGFR1 and FGFR2, and the spectrum of downstream signaling proteins with which these receptors physiologically interact.
RESULTS

bFGF-induced calcium signals in wild-type human diploid fibroblasts
The new generation of calcium-indicator fluorescent dyes have revolutionized the measurement of intracellular calcium signaling in living cells (22) . Uncharged esterified precursor dye passively equilibrates across the cell membrane, becoming loaded into intact cells because of intracellular esterase activity that releases charged unesterified active dye, trapping it in the cytoplasmic compartment. All cells of every shape and size are loaded simultaneously without needing microinjection or membrane damage. Furthermore the dyes' spectral properties allow for the calibrated conversion of dye signal into an intracellular calcium concentration while compensating for differences in cell thickness or dye photobleaching. This is accomplished by ratioing the dye signal recorded at two different wavelengths. Today's high sensitivity video cameras and rapid image processors allow one to perform this ratiometric operation for each pixel element of a video image of a field of cells. Thus, multiple single cells or even subcellular regions of cells in the field of view can be visualized, analyzed and measured simultaneously. A rapid repetitive resampling of a given field over time reconstructs the intracellular calcium signal from each element in the field as it responds to extracellular stimuli (22) . The ability to examine single cells in this detail has uncovered a richness of signaling phenotypes which are invisible in an integrated population average. This is because some stimuli, such as growth factors, do not trigger responses in every cell, and because those cells that do respond show a variable latency, signal pattern and phase. Empirically, cells have a robust response to growth factors when serum deprived (23), therefore we chose as our standard conditions the response of serum-deprived human diploid fibroblasts to the addition of 50 ng/ml bFGF in Ringer solution, a supramaximal dose for triggering intracellular calcium waves (data not shown).
As illustrated in Figure 1 , during the first minute of baseline, agonist-free measurement, cells have a stable resting cytosolic ionized free calcium concentration of between 100 and 200 nM. Upon the addition of bFGF (indicated by the first arrow in the figure), but after a variable time lag ranging from 15 s (the time required for a 5-fold volume exchange of the bath perfusion system) to 180 s, individual cells respond asynchronously with calcium wave signals. This asynchronous response, with each cell's calcium oscillating out-of-phase with that of its neighbors, makes these signals very difficult to resolve without sophisticated single-cell analysis. In addition, the individual signals varied in the nature of the calcium wave which developed. We broadly categorized these as single transients, sustained plateaux or oscillations in the intracellular calcium concentration. The transients (Fig. 1D) typically have a duration of 1-2 min. They are indistinguishable from the first calcium wave seen in cells that go on to oscillate (Fig. 1A, B and E), and may, therefore, reflect a special case of the same response. Should oscillations ensue, the calcium waves occur at regular intervals, 2-3 min between peaks, and the amplitude of the waves diminishes with time. The sustained plateau response (Fig. 1C ) appears distinctly different, and may, in fact, be superimposed upon the oscillations (Fig. 1F ). It may be slow to rise, but has as its distinctive feature a sustained, still slower, declining phase back to baseline. At the end of each experiment, bradykinin (10 µM) was added to the cells. Bradykinin is known to act through its own G protein-coupled serpentine receptor and to mediate phosphoinositol turnover and IP3-dependent calcium release from intracellular stores (24) . The bradykinin response, therefore, served as a positive control in each experimental cell for both viability and a responsive calcium signaling pathway. It, further, served as a check on the calibration of the imaging apparatus itself. Note that not every cell responded to bFGF ( Fig. 1G and H), even though its bradykinin response was intact.
Previous studies have shown that growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF) and FGF, in binding to their receptor tyrosine kinases, mediate cytoplasmic calcium waves produced by a combination of calcium release from intracellular stores, and a sustained calcium current across the plasma membrane. In most cases, the conductance pathway can be defined as either a voltage-activated calcium channel (25, 26) , a non-selective cation channel (16, 23, 27, 28) or a capacitive calcium conductance, Icrac (29) (30) (31) .
bFGF fails to cause calcium signals in the absence of extracellular calcium (data not shown). The implication is that the bFGF-induced calcium signal in human diploid fibroblasts is dependent primarily upon extracellular calcium entering the cytoplasm, with no significant component produced by the release of intracellular calcium stores. Since the cells could resume their responses, similar to those shown in Figure 1 , after the re-addition of external calcium (data not shown), transmembrane calcium influx must be predominantly responsible for the FGFR calcium signal. These results are consistent with those in a recent detailed study of the murine Balb-c 3T3 fibroblast line by Lovisolo and co-workers (16) . These investigators found that bFGF elicited a sustained increase in intracellular calcium and that this was completely dependent upon external calcium and the continued presence of the mitogen. They also showed pharmacologically, with thapsigargin (32) , that the sustained increase in intracellular calcium did not depend upon capacitive influx. This same pharmacology appears to be present in the human fibroblasts (H.B.N., unpublished observations). The bFGF-induced calcium signal in human diploid fibroblasts, therefore, seems to be produced by a transmembrane calcium influx through an as yet undefined calcium-conducting channel.
Effect of FGFR3 mutations on the calcium signal
To define further the mechanism of bFGF-induced calcium signals in human diploid fibroblasts, and in particular to assess the effect of FGFR3 on calcium signals, we examined the bFGF response of cells with defined mutations in FGFR3. The cells studied, in addition to wild-type, carried defined mutant alleles which produced the distinctive disease phenotypes of homozygous and heterozygous Ach and TD types 1 and 2 (20, 21) . Figure  2 presents the analysis of eight representative cells having genotypes causing each of these four disease phenotypes. The studies are carried out in normal extracellular calcium, and are directly comparable with the study of wild-type control cells presented in Figure 1 . These results show that the baseline calcium concentration is indistinguishable for all four disease phenotypes, and that it is the same as found in wild-type control For all four mutant cell types, the bradykinin response appears in every way to be the same as in wild-type control cells. This is a further reassurance that the mutant cells do not have a constitutive calcium signaling phenotype. Since image analysis allows us to follow only net changes in cytosolic calcium, one might imagine the mutant cells masking an increased constitutive unidirectional calcium influx by somehow having increased unidirectional efflux. This cannot be the case, however, since this increased unidirectional efflux would have had to alter the kinetics of the bradykinin-induced calcium signal as well, contrary to what was observed.
The addition of bFGF induces calcium signals in cells with genotypes causing heterozygous Ach and heterozygous TD type 2. These signals are comparable with those of wild-type cells in morphology and duration. On the other hand, the calcium signal is largely obliterated in cells with genotypes causing heterozygous TD type 1 and homozygous Ach. Only occasionally did a cell in these fields give even an aberrant calcium signal in response to bFGF, despite the fact that they signaled perfectly normally in response to bradykinin.
To determine the reliability of the phenotypes ascertained by calcium image analysis, 18 independent cell lines having different FGFR3 alleles were examined in a single-blinded fashion for response to bFGF. Table 1 presents the response rate determined on ∼250 cells of each cell line, and Figure 3 illustrates FGFR calcium signaling and the position of the different FGFR3 mutations studied. In Table 1 , the percentage of cells responding to bFGF with any form of calcium signal is reported, and all cell lines carrying a genotype causing a given disease phenotype (three or four independent lines each) are grouped. Note the internal consistency within groups. Cells subsequently revealed to have been genotyped as homozygous Ach or heterozygous TD1 had <10% of the population responding to bFGF, and no individual line had greater than one out of six cells capable of any type of bFGF response. All of the other genotypes responded similarly to control at ∼45%. This is represented graphically in Figure 4 as the mean response rate for cells from each of the disease groups. As was Within this complex, the receptors undergo autophosphorylation on tyrosine residues. Phospholipase Cγ (PLCγ) docks on phosphotyrosine 766, becomes phosphorylated and active, cleaving phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). DAG activates protein kinase C (PKC) and IP3 releases calcium from intracellular stores by binding to an IP3 receptor. The mechanism by which the calcium conducting ion channel in the plasma membrane becomes activated remains to be determined, but the majority are not Icrac channels.
observed when comparing the morphology of calcium signals produced by cells of different genotypes, the high response rates in heterozygous Ach and heterozygous TD type 2 are comparable with that of wild-type, whereas the heterozygous TD type 1 and homozygous Ach cells rarely responded to bFGF. Ach1  53  Ach2  14  Ach3  54  Ach4  60  TD1  TD11  8  TD12  12  TD13  13  TD14  5  TD2  TD21  88  TD22  46  TD23  38  TD24  31 Approximately 250 cells from each cell line were analyzed for changes in intracellular calcium using ratiometric image analyis, as described in Materials and Methods. A cell was considered responsive if bFGF elicited a calcium signal like any of those in Figure 1A -F. Only cells responding to bradykinin were scored.
DISCUSSION
In these experiments, we show that in human diploid fibroblasts, as in previously studied model systems, calcium signaling is a useful downstream reporter of physiological FGF receptor activation, and demonstrate that this signal is predominated by a transmembrane calcium influx. We further show that we can use this physiological reporter function to assign a signaling phenotype to single cells, and that the phenotype is highly correlated with certain FGFR3 disease phenotypes. A coherent interpretation of our results requires us to posit that the mutant FGFR3 alleles function to disrupt signaling in a dominant-negative manner. The results are inconsistent with a constitutive functional activation of signaling by the mutant receptors since the mutant and wild-type cells have the same stable, low basal intracellular calcium concentration during serum starvation, and achieve comparable calcium waves of comparable magnitude and duration during control bradykinin or ATP (not shown) activations. This is also consistent with the well-established observation that these alleles lack any oncogenic potential in vivo or in vitro (1, 9) . A dominant-negative interaction, on the other hand, is implied since cells of specific FGFR3 mutant genotypes faithfully remain at basal calcium concentrations after supramaximal bFGF stimulation, a result that could not be achieved without the mutant allele acting through some novel gained function to silence all receptor responses to bFGF. The means by which the mutant receptors achieve negative dominance remains to be determined but, based upon prior studies of engineered dominant-negative FGFR alleles in cells and embryos (12, 13) , they must disturb signaling by all expressed allelic and non-allelic FGFRs, most likely through the formation of signaling-incompetent, ligand-dependent or -independent heteromultimers in the plasma membrane. Table  1 ; 47 ± 19% of wild-type cells responded. This compares with 45 ± 21% of heterozygous Ach cells and 50 ± 25% of heterozygous TD2 cells, and contrasts with the low response rates of homozygous Ach and heterozygous TD1 cells, having only 8 ± 8% and 10 ± 4% responses, respectively.
We have found that a single copy of either ligand-binding domain TD1 allele tested (R248C or S371C), or homozygosity for the common transmembrane domain Ach allele (G380R), inhibits all Ca 2+ signaling induced by bFGF. This is a faithful and predictive, possibly diagnostic, correlate of their characteristic lethal phenotypes. The fact that all bFGF-dependent Ca 2+ signaling is abolished by these genotypes at the FGFR3 locus suggests that the abnormal FGFR3 in some way interferes with signaling by the other expressed allelic and non-allelic wild-type FGF receptors. This finding is comparable with prior work from Williams' laboratory (12, 14) demonstrating that a dominantnegative form of FGFR1 inhibits bFGF-induced signal transduction by wild-type FGFR1, 2 and 3 co-expressed in Xenopus oocytes or natively expressed in mouse skin. Furthermore, in the oocyte (12) , an abundance threshold of the inhibitory receptor could be defined, below which the mutant could no longer inhibit the wild-type receptor's calcium signaling. This dosage dependence of the inhibition is similar to what we observe with the G380R Ach allele, where the homozygous but not the heterozygous state is inhibitory.
The same line of reasoning used to interpret gene dosage can be extended to the notion of allele potency when comparing the effect of mutations in different domains of FGFR3. Our observations suggest that a critical aggregate level of receptor activity must be induced by ligand binding to allow physiological calcium signaling to occur. Just as two copies of the G380R allele leave receptor activity below threshold, even one copy of any of the TD1 alleles prevents calcium signaling. Therefore the TD1 alleles must be more disruptive dominant-negative alleles than the G380R allele. This increased potency might arise because of increased avidity in interactions with other receptor monomers, or it might arise by interference at a different, more sensitive step in the signaling pathway. One copy of the TD2 kinase domain allele, K650E, however, is not sufficient to suppress calcium signaling. The implication is that the TD2 allele is less disruptive or potent than the TD1 alleles, again either because of a lesser avidity at the same site acted upon by TD1 or because it acts at a less sensitive step in the signaling pathway. Because the disease phenotype produced by a single TD2 allele is much more severe than that produced by a single G380R Ach allele, the TD2 allele must be more disruptive than the G380R allele. This would give an overall dominant-negative allele potency of TD1>TD2>Ach.
Because an equivalently severe perinatal-lethal disease phenotype is produced by homozygous Ach, and heterozygous TD1 and TD2, the dominant-negative hypothesis suggests two further corollaries. First, the disruptive potency of the homozygous G380R genotype is severe, but incompletely determined, being either more severe than both TD1 and TD2 or intermediate between the two. This would order the disruptive potency of the genotypes as (HAch∼TD1)>fibroblast threshold>TD2>Ach. Second, the tissue most critical to the pathogenesis of the syndromes (perhaps the embryonic endochondral growth plate chondrocytes) must be more sensitive to FGF signaling than our fibroblast model cells, such that even a single achondroplasia allele has some effect, giving an order: (HAch∼TD1)>fibroblast threshold>TD2>(critical tissue threshold∼Ach)>WT.
The model we propose for the pathogenesis of the FGFR3 diseases, which suggests that the primary mechanism of disease is a dominant-negative interference with all FGFR signaling, is not necessarily incompatible with certain aspects of mutant receptor function appearing to be constitutively active, as has been reported by others using transfected chimeric receptors (7-10 and reviewed in 1). Those studies most clearly established that the change in amino acid sequence produced by the FGFR disease mutant alleles renders the affected receptor more susceptible to ligand-independent multimerizatrion than the wild-type sequence. What is not clear is whether this ligand-independent multimerizatrion produces an increased or decreased signal in native tissue. If, in fact, the mutant FGFR proteins are capable of ligand-independent multimerization, not just with themselves (the only possibility in the above studies where they are the sole species of receptor expressed), but with wild-type FGFR1, FGFR2 and FGFR3 proteins as well (as occurs physiologically), and if, as reported by Naski et al. (10) , even the wild-type FGFR3 cytoplasmic domain signals poorly, the 'avidly associating' mutant FGFR3 proteins must preferentially consume into relatively inactive signaling complexes receptor monomers that would otherwise physiologically associate randomly in the presence of ligand, and thereby signal more potently. Further, if, again as reported by these investigators (9, 10) , there is a different tendency of the different disease variants of FGFR3 to multimerize, there will be a graded phenotype produced. Finally, if the conformation of a pathological, ligand-independent receptor multimer of any FGFR type is less suitable to signaling than the physiological, ligand-induced multimer, then perhaps the same mechanism proposed for the diseases of the weakly signaling FGFR3 applies to the FGFR1 and FGFR2 diseases as well, and further helps explain why the different disease alleles in the different genes are so similar structurally, why they produce constitutive multimers and why they lack the oncogenic potential found in most constitutively active growth factor receptors (33) .
It remains to be demonstrated what the phenotype observed in homozygous null mice (5,6) reveals about the pathophysiology of the mutant FGFR3 alleles, since nulls cannot reveal the nature of a novel 'gained' function. Another factor recently shown to complicate the analysis of members of gene families, such as the FGFRs, in knockout mice, is that a compensatory isoform switch in gene expression has been recognized to occur, capable of producing a paradoxical phenotype in the knockout animal that reflects the presence of the newly overproduced isoform more than the absence of the targeted product (34) .
A definition of signaling downstream from activated FGFRs is only beginning to emerge. The story is complicated since these receptors have been implicated in mitogenesis, differentiation, apoptosis and chemotaxis, with no suggestion as to how these different signals might be orchestrated (11, 33) . Further, the FGFR signal lags behind the better understood PDGFR and EGFR pathways to a large extent because SH2 domain-mediated macromolecular assemblies of signaling proteins on receptor phosphotyrosine residues (33) (36) , and there has even been a suggestion that it plays a larger role in mesodermal differentiation than in mitosis (37) . Our hope is that a further understanding of the calcium signaling defects produced by the FGFR mutant alleles will lead to a better understanding of the nature of FGFR signal transduction, and that this in turn will point to directions for rational therapy of the FGFR diseases.
MATERIALS AND METHODS
Cell culture
Genotyped human fibroblast cell cultures were generously provided by Dr J. J. Wasmuth (UC Irvine). Cells were maintained in tissue culture flasks in Dulbecco's minimum essential medium (DMEM) containing 10% fetal bovine serum at 37_C in an atmosphere of 95% air and 5% CO 2 . For each experiment, cells were plated at low density in the same growth medium on custom-made glass coverslip chambers. After 4-5 days of exponential growth, cells were G 0 -arrested by culturing in serum-free DMEM medium for the final 24 h preceding imaging.
Intracellular calcium measurements
The cells were loaded with calcium indicator dye by performing a 1 h incubation at 37_C in serum-free DMEM containing 4 µM fura-PE3 (Teflabs). After loading, the cells were washed and maintained in standard extracellular Ringer solution composed of (in mM) 160 NaCl, 4 KCl, 2.0 CaCl 2 , 1 MgCl 2 , 5 HEPES, and 10 glucose, adjusted to pH 7.2. For ratiometric imaging of intracellular calcium, light from a 75 W xenon arc lamp was passed through a motorized filter wheel containing 340 and 380 nm filters and a field of the dye-loaded cells imaged using a Zeiss IM 35 inverted microscope. Dye fluorescence was captured by a Hamamatsu C2400 SIT camera, and the signal was processed by a video imaging system (ETM Systems). Eight-bit images, averaged over eight frames, were recorded every 8 s for each wavelength. The raw images were first background subtracted and the resulting images were divided to obtain ratios of the fluorescence at 340 nm/380 nm. Regions of the image were defined to correspond to individual cells, and the intracellular calcium (the fluorescence ratio) within each defined region was followed during the course of the experiment. Depending upon the density of the cells in a culture, between 10 and 50 cells could be distinguished simultaneously in the imaged field of view. This generates a matrix of intracellular calcium measurements, reported as fluorescence ratios, for each region (cell) versus time. These values are transferred to a spreadsheet program (Sigmaplot) for analysis and figure generation. For dye calibration, the minimal fluorescence ratio, R min , was measured using 1 µM ionomycin in Ringer solution buffered to 10 nM CaCl 2 (0.1 mM calcium, 11 mM EGTA) and the maximal fluorescence ratio, R max , was similarly measured with Ringer solution supplemented to 10 mM CaCl 2 . Conversion of the fluorescence ratio to a Ca 2+ concentration was performed according to Grynkiewicz et al. (38) .
All experiments were performed at room temperature. The solution in the chamber could be replaced using a perfusion system that takes ∼15 s for a 5-fold volume exchange. The bFGF (R & D Systems), bradykinin (Calbiochem) and ATP (Sigma) were solubilized in water as 1000× stocks and stored as single-use aliquots at -30_C. These reagents were diluted into Ringer solution at their final concentrations on the day of experiment.
Statistics
Basic statistical analysis of means and standard deviations were calculated using either Excel or Sigmastat. Comparisons of datasets by ANOVA were performed using Sigmastat.
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ABBREVIATIONS
FGFR, fibroblast growth factor; receptor type denoted by numeral 1-3; bFGF, basic fibroblast growth factor, also called FGF2; Ach, achondroplasia; Hach, homozygous achondroplasia; TD, thanatophoric dysplasia; type denoted by numeral 1 or 2; WT, wild-type; PDGF/PDGFR, platelet derived growth factor/and its receptor; EGF/EGFR, epidermal growth factor/and its receptor; RT-PCR, reverse transcription-polymerase chain reaction; Icrac, calcium release activated current; PLCγ, phospholipase Cγ; SH2, src homology 2 domain; HEPES, N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid]; EGTA, ethyleneglycol-bis-(betaamino ethyl ether) N,N′-tetra acetic acid.
